Even Light Exercise Could Help Slow Cognitive Decline in People at Risk of Alzheimer’s

The EXERT study was supported through the National Institutes of Health/National Institute on Aging (U19AG010483-25 and AG058644) and by the Brain Research Foundation (BRF ECD-2014-01).

Disclosures: Feldman receives grant funding from the National Institute on Aging (U19AG010483-22), from Biohaven Pharmaceuticals, Vivoryon (Probiodrug), and LuMind Foundation; service agreements for consulting activities with LuMind, Axon Neuroscience, Novo Nordisk, Arrowhead Pharmaceuticals, Roche/Genentech Pharmaceuticals (DMC/DSMB), Tau Consortium (SAB), and Janssen Research & Development (DSMB); support for travel from Novo Nordisk, Royal Society of Canada, Translating Research in Elder Care (TREC), Association for Frontotemporal Dementia (AFTD), and Rainwater Charitable Foundation; and a philanthropic donation for the Epstein Family Alzheimer Research Collaboration. No personal funds have been received for these activities. Feldman personally receives royalties for patent: Feldman HH (filed November 26, 2008). Detecting and Treating Dementia Serial Number 12/3-2691 U.S. Patent No. PCT/US2007/07008. Washington, DC: U.S. Patent and Trademark Office.

Link to the second study.

Additional co-authors of the additional study include Diane M. Jacobs, David P. Salmon, Rosemary Morrison, Shelia Jin, Ronald G. Thomas, Andrea Z. LaCroix, Judy Pa and Carl W. Cotman at UC San Diego, Vahan Aslanyan at University of Southern California and Jeffrey A. Katula at Wake Forest University.

Disclosures: Howard Feldman receives grant funding from the National Institute on Aging (U19AG010483), from Biohaven Pharmaceuticals, Vivoryon (Probiodrug), Allyx Therapeutics, and LuMind Foundation; service agreements for consulting activities with LuMind, Axon Neuroscience, Novo Nordisk, Biosplice Therapeutics, Arrowhead Pharmaceuticals, Roche/Genentech Pharmaceuticals (DMC/DSMB), Tau Consortium (SAB), Janssen Research & Development (DSMB); support for travel from Novo Nordisk, Royal Society of Canada, Translating Research in Elder Care (TREC), Association for Frontotemporal Dementia (AFTD), and Rainwater Charitable Foundation; and a philanthropic donation for the Epstein Family Alzheimer Research Collaboration. Feldman also receives royalties for patent: Feldman HH (filed November 26, 2008). Detecting and Treating Dementia Serial Number 12/3- 2691 US Patent No. PCT/US2007/07008. Washington, DC: U.S. Patent and Trademark Office. Baker reports grant funding from NIH (U19 AG010483, AG062689, AG066910, U19 AG063744, P30AG049638- 01A1, HL 133684-01A1, AG064440, U24 AG057437) and Alzheimer’s Association (POINTER-19-611541), honoraria from Washington State University and National Academy of Neuropsychology, payments from Alzheimer’s Association and Oregon State University for invited speakerships, and participation in the Data Safety Monitoring Board for the Alzheimer Center at Washington State University. Katula reports funding from NIH (U19 AG010483) and Alzheimer’s Association, and participation in the Data Safety Monitoring Board for South Asians Active Together (SAATH) study. Morrison reports funding from NIA (U19 AG010483). LaCroix reports NIA funding from ADCS. Shadyab reports funding from NIH/NIA (U19 AG010483). Jacobs reports funding from NIH/NIA, Biohaven Pharmaceuticals, Vivoryon Therapeutics, and the Epstein Family Alzheimer Research Collaboration.